Fig. 1.
RU486 abrogates agonist-dependent PRA and PRB down-regulation and transcriptional activity. Ishikawa or MDA-MB-231 cells stably expressing PRA or PRB were treated either by vehicle or R5020 (10−8 m) alone or in combination with RU486 (10−6 m) during either 6 h for the analysis of FKBP5 gene transcripts by real time quantitative PCR (lower panel) or 24 h for immunoblot detection of PR isoforms using anti-PR antibody (upper panel). Statistical significance is shown for agonist-induced transactivation as compared with vehicle-treated cells (asterisks) or for comparison between agonist alone or with antagonist-treated cells (XX).